Literature DB >> 11390600

Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter.

R W Tindle1, K Herd, T Doan, G Bryson, G R Leggatt, P Lambert, I H Frazer, M Street.   

Abstract

The E7 oncoprotein of human papillomavirus 16 (HPV16) transforms basal and suprabasal cervical epithelial cells and is a tumor-specific antigen in cervical carcinoma, to which immunotherapeutic strategies aimed at cytotoxic T-lymphocyte (CTL) induction are currently directed. By quantifying major histocompatibility complex class I tetramer-binding T cells and CTL in mice expressing an HPV16 E7 transgene from the keratin-14 (K14) promoter in basal and suprabasal keratinocytes and in thymic cortical epithelium, we show that antigen responsiveness of both E7- and non-E7-specific CD8+ cells is down-regulated compared to non-E7 transgenic control mice. We show that the effect is specific for E7, and not another transgene, expressed from the K14 promoter. Down-regulation did not involve deletion of CD8+ T cells of high affinity or high avidity, and T-cell receptor (TCR) Vbeta-chain usage and TCR receptor density were similar in antigen-responsive cells from E7 transgenic and non-E7 transgenic mice. These data indicate that E7 expressed chronically from the K14 promoter nonspecifically down-regulates CD8+ T-cell responses. The in vitro data correlated with the failure of immunized E7 transgenic mice to control the growth of an E7-expressing tumor challenge. We have previously shown that E7-directed CTL down-regulation correlates with E7 expression in peripheral but not thymic epithelium (T. Doan et al., J. Virol. 73:6166-6170, 1999). The findings have implications for the immunological consequences of E7-expressing tumor development and E7-directed immunization strategies. Generically, the findings illustrate a T-cell immunomodulatory function for a virally encoded human oncoprotein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390600      PMCID: PMC114314          DOI: 10.1128/JVI.75.13.5985-5997.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Peripheral T cell tolerance.

Authors:  J F Miller; G Morahan
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

2.  Chronic modulation of the TCR repertoire in the lymphoid periphery.

Authors:  C A Blish; B J Gallay; G L Turk; K M Kline; W Wheat; P J Fink
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

3.  Levels of peripheral T cell tolerance induced by different doses of tolerogen.

Authors:  I Ferber; G Schönrich; J Schenkel; A L Mellor; G J Hämmerling; B Arnold
Journal:  Science       Date:  1994-02-04       Impact factor: 47.728

4.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

Authors:  C Yee; P A Savage; P P Lee; M M Davis; P D Greenberg
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

5.  Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.

Authors:  M C Feltkamp; H L Smits; M P Vierboom; R P Minnaar; B M de Jongh; J W Drijfhout; J ter Schegget; C J Melief; W M Kast
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

6.  Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions.

Authors:  M von Knebel Doeberitz; C Rittmüller; F Aengeneyndt; P Jansen-Dürr; D Spitkovsky
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

7.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Authors:  K Y Lin; F G Guarnieri; K F Staveley-O'Carroll; H I Levitsky; J T August; D M Pardoll; T C Wu
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

8.  Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.

Authors:  M E Ressing; W J van Driel; E Celis; A Sette; M P Brandt; M Hartman; J D Anholts; G M Schreuder; W B ter Harmsel; G J Fleuren; B J Trimbos; W M Kast; C J Melief
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

9.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

Authors:  M E Ressing; A Sette; R M Brandt; J Ruppert; P A Wentworth; M Hartman; C Oseroff; H M Grey; C J Melief; W M Kast
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

10.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex.

Authors:  A Vitiello; D Marchesini; J Furze; L A Sherman; R W Chesnut
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

View more
  9 in total

1.  Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.

Authors:  Nicholas C Souders; Duane A Sewell; Zhen-Kun Pan; S Farzana Hussain; Alexander Rodriguez; Anu Wallecha; Yvonne Paterson
Journal:  Cancer Immun       Date:  2007-02-06

2.  Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms.

Authors:  John M Routes; Kristin Morris; Misoo C Ellison; Sharon Ryan
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

Review 4.  The tug-of-war between dendritic cells and human chronic viruses.

Authors:  Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

5.  Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model.

Authors:  Tiffany Brake; Paul F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

6.  Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.

Authors:  Michael D Street; Tracy Doan; Karen A Herd; Robert W Tindle
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

7.  Langerhans cell homeostasis and activation is altered in hyperplastic human papillomavirus type 16 E7 expressing epidermis.

Authors:  Nor Malia Abd Warif; Patrizia Stoitzner; Graham R Leggatt; Stephen R Mattarollo; Ian H Frazer; Merilyn H Hibma
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

8.  Suppression of the CD8 T cell response by human papillomavirus type 16 E7 occurs in Langerhans cell-depleted mice.

Authors:  K Jemon; C-M Leong; K Ly; S L Young; A D McLellan; M H Hibma
Journal:  Sci Rep       Date:  2016-10-06       Impact factor: 4.379

9.  Therapeutic vaccines against human papillomavirus and cervical cancer.

Authors:  Angel Cid-Arregui
Journal:  Open Virol J       Date:  2009-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.